CROI 2017 Abstract e-Book

Abstract eBook

Poster and Themed Discussion Abstracts

820 EFFECTS OF CALCIUM AND VITAMIN D SUPPLEMENTATION ON BONE HEALTH IN HIV-INFECTED YOUTH Tavitiya Sudjaritruk 1 , Linda Aurpibul 1 , Torsak Bunupuradah 2 , Suparat Kanjanavanit 3 , Tawalchaya Chotecharoentanan 1 , Sineenart Taejaroenkul 1 , Pradthana Ounchanum 4 , Piyarat Suntarattiwong 5 , Thanyawee Puthanakit 6 , for the CAL-D Study Group 1 Chiang Mai Univ, Chiang Mai, Thailand, 2 HIV Netherlands Australia Thailand Rsr Collab (HIV-NAT), 3 Nakornping Hosp, Chiang Mai, Thailand, 4 Chiang Rai Prachanukroh Hosp, Chiang Rai, Thailand, 5 Queen Sirikit Natl Inst of Child Hlth, Bangkok, Thailand, 6 Chulalongkorn Univ, Bangkok, Thailand Background: Adverse bone health is an important complication in people living with HIV. Calcium and vitamin D (Ca/VitD) supplementation have demonstrated beneficial impacts on bone health. This study aimed to evaluate effects of Ca/VitD supplementation on bone metabolism and bone mineral density (BMD) in HIV-infected Thai youth. Methods: An ongoing, multicenter, 48-week, randomized, open-label trial has been conducted. Perinatally HIV-infected adolescents (10-20 years) with viral suppression (HIV RNA<400 copies/ml) were randomized to receive calcium (1.2 g/day) and high-dose vitamin D (3200 IU/day) (high-dose group) or calcium (1.2 g/day) and normal-dose vitamin D (400 IU/day) (normal-dose group) for 48 weeks. BMD (primary outcome) was assessed at baseline and 48 weeks. Bone metabolism-related markers (secondary outcomes), including serum 25-hydroxyvitamin D (25OHD), intact parathyroid hormone (iPTH), alkaline phosphatase (ALP), and bone turnover markers (C-terminal cross-linked telopeptide of type I collagen [CTX; bone resorption marker], and procollagen type I amino-terminal propeptide [PINP; bone formation marker]) were measured at baseline, 24 and 48 weeks. Preliminary intention-to-treat analyses were conducted at 24 weeks using Wilcoxon rank sum and signed rank tests. Models stratified by baseline BMD (Z-score≤-2 vs. >-2) were also performed. Results: From April 2015 to April 2016, 166 adolescents (83 each group) were enrolled. The population was 48%male; 35% receiving protease inhibitor-based cART. Median age was 16 years; CD4 count 711 cells/mm3. Median baseline BMD Z-score was -1.5; 67 (40%) had Z-score ≤-2. Overall adherence to Ca/VitD supplementation was 85%. At baseline, the study groups were well-balanced. At 24 weeks, serum 25OHD levels were increased (P<0.001), whereas iPTH, ALP, CTX, and PINP were declined (P<0.001) in both treatment groups. There was no difference in all bone metabolismmarkers observed between high- versus normal-dose vitamin D group (P>0.05) (Table1). Models stratified by baseline BMD yielded similar results. Two subjects (high-dose group) discontinued due to toxicities (acne; constipation). Conclusion: Ca/VitD supplementation for 24 weeks increased serum 25OHD, decreased iPTH levels and re-established bone turnover dysregulation among adolescents in our cohort. Supplementation with high-dose vitamin D did not show difference in bone metabolism outcomes compared to normal-dose. Evaluation of the impact of Ca/VitD supplementation on bone mineral density is underway.

Poster and Themed Discussion Abstracts

821 METABOLIC PROFILES OF ADULTS VERTICALLY INFECTED WITH HIV AND THE GENERAL POPULATION Elise Arrivé 1 , Jean-Paul Viard 2 , Elisa Arezes 3 , Feriel Ayat 3 , Benoit Salanave 4 , Sophie Matheron 5 , Véronique Reliquet 6 , Corinne Vigouroux 7 , Josiane Warszawski 3 , for the ANRS CO19 COVERTE Study Group 1 Univ of Bordeaux, Bordeaux, France, 2 Hôtel-Dieu de Paris, Paris, France, 3 INSERM, Le Kremlin-Bicêtre, France, 4 Equipe de Surveillance et d’Epidémiologie Nutritionnelle/Agence Natl de Santé Publique, Bobigny, France, 5 Bichat-Claude Bernard Hosp, Paris, France, 6 CHU Hôtel Dieu, Nantes, France, 7 INSERM, Paris, France Background: Cardiometabolic risk is poorly documented for the first generation of young adults living with HIV since childhood and exposed to synergic risk factors, including antiretroviral drugs (ARV), lipodystrophy and HIV itself. We compared the metabolic profiles of these young adults and the general population of the same age in France. Methods: We used two French national studies: (1) COVERTE (ANRS-CO19), a cohort of 18- to 30-year-old patients infected with HIV since childhood, and (2) ENNS, a national cross- sectional population-based household nutrition survey. Body mass index, blood pressure, waist circumference, fasting glucose, triglycerides, HDL-, LDL- and total cholesterol were determined in both studies. Metabolic abnormalities were categorized according to the Joint Interim Statement definition of metabolic syndrome (2009). Their prevalences were

CROI 2017 355